
News
Press Releases
Year:
2010 | 2009 | 2008
| September 1, 2010 | Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC
| | August 30, 2010 | Genzyme Confirms Receipt of Unsolicited Proposal
| | August 23, 2010 | Two-Year Data from Phase 2 Trial of Genzyme’s Eliglustat Tartrate for Gaucher Disease To Be Published in the Journal Blood
| | August 4, 2010 | Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen
| | July 27, 2010 | Genzyme Encouraged by CMS Decision to Delay Oral Drug Inclusion in Dialysis Patient Benefit
| | July 21, 2010 | Genzyme Reports Financial Results for the Second Quarter of 2010
| | June 18, 2010 | Genzyme Announces Accelerated Share Repurchase
| | June 16, 2010 | Shareholders Re-Elect All Members of Genzyme’s Board of Directors
| | June 15, 2010 | Genzyme Prices Private Senior Notes Offerings
| | June 14, 2010 | Genzyme’s Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDA
| | June 9, 2010 | Genzyme and Carl Icahn Reach Agreement
| | June 7, 2010 | Dennis Fenton Nominated for Election to Genzyme’s Board of Directors
| | May 25, 2010 | Genzyme Receives FDA Approval for Lumizyme for Pompe Disease
| | May 24, 2010 | Genzyme Announces Final Terms of FDA Consent Decree
| | May 6, 2010 | Genzyme Announces $2 Billion Stock Repurchase
| | April 21, 2010 | Genzyme Reports Financial Results for the First Quarter of 2010
| | April 15, 2010 | Genzyme Study of Myozyme Treatment for Pompe Disease Published in New England Journal of Medicine
| | April 15, 2010 | Ralph Whitworth Elected to Genzyme’s Board of Directors
| | April 14, 2010 | Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically-Active Disease
| | April 8, 2010 | Genzyme Sets June 16 Date for Annual Meeting of Shareholders
| | March 31, 2010 | Genzyme to Host Investor Event on Its Manufacturing Operations
| | March 30, 2010 | Genzyme Creates Chief Operating Officer Position
| | March 24, 2010 | Genzyme Announces FDA Enforcement Action Regarding Allston Plant
| | March 15, 2010 | Mipomersen Phase 3 Study in HoFH Patients Featured in The Lancet
| | March 3, 2010 | PTC Therapeutics and Genzyme Corporation Announce Preliminary Results from the Phase 2b Clinical Trial of Ataluren for Nonsense Mutation Duchenne/Becker Muscular Dystrophy
| | February 22, 2010 | Genzyme Receives Notice of Icahn Partners’ Nomination of Directors
| | February 17, 2010 | Genzyme Reports Financial Results for Fourth Quarter of 2009 and Full Year
| | February 11, 2010 | Two-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Continued Improvement Across All Endpoints
| | February 10, 2010 | Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint
| | February 3, 2010 | Scott Canute Joins Genzyme to Head Manufacturing and Corporate Operations
| | January 29, 2010 | Genzyme Strengthens Role of Board’s Lead Independent Director
| | January 28, 2010 | Genzyme Adopts New Incentive Compensation Plans for Senior Executives
| | January 21, 2010 | Genzyme’s Lumizyme BLA Receives Six-Month FDA Review
| | January 12, 2010 | Genzyme Reports Fourth-Quarter Revenue
| | January 8, 2010 | Industry Veteran Ron Branning Joins Genzyme to Lead Global Product Quality
| | January 7, 2010 | Genzyme and Relational Investors Enter Into Mutual Cooperation Agreement
|
|
 |


 |
 |
CONTACT INFORMATION: |
 |
Genzyme Media Relations
500 Kendall Street
Cambridge, MA 02142
T 617 252 7570
F 617 374 7368
Email Media Relations
|
 |
 |
|